Antitumor effects of combined granulocyte macrophage colony stimulating factor and macrophage inflammatory protein-3 alpha plasmid DNA.
Dendritic cells (DC) are critical for priming adaptive immune responses to foreign antigens. However, the feasibility of harnessing these cells in vivo to optimize the antitumor effects has not been fully explored. The authors investigated a novel therapeutic approach that involves delivering synergistic signals that both recruit and expand DC populations at sites of intratumoral injection. More specifically, the authors examined whether the co-administration of plasmids encoding the chemokine macrophage inflammatory protein-3 alpha (pMIP3α) and plasmid encoding the granulocyte macrophage colony stimulating factor (pGM-CSF; a DC-specific growth factor) can recruit, expand and activate large numbers of DC at sites of intratumoral injection. It was found that the administration of pGM-CSF and pMIP3α resulted in dramatic recruitment and expansion of DC at these sites and in draining lymph nodes. Furthermore, treatment with pGM-CSF and pMIP3α generated the strongest MUC1-associated CD8+ T-cell immune responses in draining lymph nodes and in tumors, produced the greatest antitumor effects and enhanced survival rates more than pcDNA3.1, pGM-CSF alone and pMIP3α alone. It was also found that pGM-CSF plus pMIP3α generated the strongest MUC1-associated CD4+ T-cell immune responses in draining lymph nodes and in tumors. The findings of the present study suggest that the recruitment and activation of DC in vivo due to the synergistic actions of pGM-CSF and pMIP3α presents a potentially feasible means of controlling immunogenic malignancies and provides a basis for the development of novel immunotherapeutic treatments.
Choi
Yun
Y
Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.
Kim
Chul W
CW
D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D002452:Cell Count; D045744:Cell Line, Tumor; D054418:Chemokine CCL20 / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D003713:Dendritic Cells / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005240:Feasibility Studies; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D018396:Mucin-1 / Q000235:genetics / Q000276:immunology; D009374:Neoplasms, Experimental / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D010957:Plasmids / Q000008:administration & dosage / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016019:Survival Analysis; D047368:Tumor Burden / Q000276:immunology
D054418:Chemokine CCL20; D018396:Mucin-1; D007371:Interferon-gamma; D016178:Granulocyte-Macrophage Colony-Stimulating Factor
Cancer Immunol Immunother. 2004 Jan;53(1):17-25
12955480
J Biol Chem. 1997 Jun 6;272(23):14893-8
9169459
Nature. 1998 Mar 19;392(6673):245-52
9521319
J Clin Invest. 2004 Mar;113(5):774-83
14991076
J Immunol. 2002 May 15;168(10):4871-80
11994436
Mol Ther. 2007 May;15(5):1007-15
17356539
J Immunol. 1999 Jul 1;163(1):174-83
10384114
Cancer Lett. 1996 Mar 29;101(2):257-61
8620478
Annu Rev Immunol. 2000;18:245-73
10837059
J Exp Med. 1998 Jul 20;188(2):373-86
9670049
Cell. 2001 Aug 10;106(3):271-4
11509176
Science. 1999 Dec 10;286(5447):2098-102
10617422
J Immunol. 2000 Feb 15;164(4):1995-2000
10657650
Cancer Res. 2000 Feb 15;60(4):1035-42
10706121
Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539-43
8097319
Semin Immunol. 2007 Feb;19(1):48-55
17276695
Immunity. 1998 Dec;9(6):757-63
9881966
Microbes Infect. 2000 Mar;2(3):257-72
10758402
Transplantation. 2002 Jan 15;73(1 Suppl):S7-11
11810053
Med Oncol. 1996 Sep;13(3):155-60
9106174
Curr Opin Immunol. 1997 Feb;9(1):10-6
9039784
J Immunol. 2003 Sep 1;171(5):2374-83
12928384
Hum Immunol. 1999 Jul;60(7):562-7
10426272
J Cancer Res Clin Oncol. 1995;121(9-10):587-92
7559742
J Exp Med. 1997 Sep 15;186(6):837-44
9294138
J Immunol. 2000 Oct 1;165(7):3797-803
11034385
J Immunol. 2005 May 15;174(10):5994-6004
15879092
Cancer. 2003 Jan 1;97(1):186-200
12491520
J Immunol. 1999 Jan 1;162(1):186-94
9886385
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13722-7
11717433
Cancer Immunol Immunother. 1996 May;42(4):237-45
8665571
Hum Gene Ther. 1997 Jun 10;8(9):1065-72
9189764
J Exp Med. 1999 Jul 5;190(1):125-33
10429676
Cancer Gene Ther. 1996 Jan-Feb;3(1):39-47
8785710
J Immunol. 2000 Sep 1;165(5):2850-8
10946318
J Immunol. 2001 Nov 1;167(9):5077-83
11673517
J Immunol. 2002 Sep 15;169(6):2875-85
12218100
Springer Semin Immunopathol. 2000;22(4):345-69
11155441